Cardax is focused on marketing ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health.*

 

Cardax previously focused on developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play key causative roles.

 

Cardax aims to build consumer sales with a reduced corporate cost structure to improve operating cash flow and achieve profitability. Cardax may seek to monetize its pharmaceutical assets through licensing or sale.

About Cardax (Ticker: CDXI)

Cardax is a consumer health company focused on marketing ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health.* ZanthoSyn® is available through Cardax’s commercial website, www.zanthosyn.com.

Cardax previously focused on development of pharmaceuticals for diseases driven by inflammation. Cardax may seek to monetize CDX-101, the Company’s pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company’s pre-clinical pharmaceutical candidate for macular degeneration.

Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. More than 50 human clinical trials supporting the safety and efficacy of astaxanthin have been conducted to date. As the broader scientific community has discovered the health benefits of astaxanthin, awareness and demand for astaxanthin has grown dramatically.